Efficacy and safety of bilastine in allergic diseases therapy

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


This review is devoted to analyses of data on efficacy and safety of bilastine in allergic diseases therapy.

Full Text

Restricted Access

About the authors

E S Fedenko

Institute of Immunology

Email: efedks@gmail.com
Moscow, Russia

O A Erina

Institute of Immunology

Moscow, Russia

O G Elisyutina

Institute of Immunology

Moscow, Russia


  1. Козулина И.Е., Курбачева О.М., Ильина Н.И. Аллергия сегодня. Анализ новых эпидемиологических данных. Рос. Аллергол. Журн. 2014, № 3, с. 3-10.
  2. Федоскова Т.Г., Ильина Н.И. Аллергические заболевания в клинической практике. РМЖ. 2005, № 15, с. 1022.
  3. Emanuel M.B. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin. Exp. Allergy. 1999, v. 29, p. 1-11.
  4. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: «Фармаруспринт». 1998, с. 252.
  5. Simons F.E.R. Advances in Н1-antihistamines. N. Engl. J. Med. 2004, v. 351, р. 2203-2217.
  6. Church D.S., Church M.K. Pharmacology of antihistamines. World Allergy Organ. J. 2011, v. 4, р. 22-27.
  7. Estelle F., Simons R. Н1-receptor antagonist safety issues. Ann. Allergy. Asthma Immunol. 1999, v. 83, p. 481-488.
  8. Simons F.E.R., Simons K.J. Н1-antihistamines: Current status and future directions. World Allergy Organ. J. 2008, v. 1, p. 145-155.
  9. Holgate S.T., Canonica G.W., Simons F.E. et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clinical & Experimental Allergy. 2003, v. 33, p. 1305-1324.
  10. Wolthers O.D. Bilastine: a new nonsedating oral Н1-antihistamine for treatment of allergic rhinoconjunctivitus and urticaria. Biomed. Res. Int. 2013.
  11. Ridolo E., Montagni M., Bonzano L. et al. Bilastine: new insight into antihistamine treatment. Clin. Mol. Allergy. 2015, v. 13, p. 1.
  12. Sadaba B., Gomez-Guiu A., Azanza J.R. et al. Oral availability of bilastene. Clin. Drug. Investig. 2013, v. 33, p. 375-381.
  13. Lucero M.L., Gonzalo A., Ganza A. et al. Interactions of bilastine, a new oral Н1-antihistamine with human transporter systems. Drug. Chem. Toxicol. 2012, v. 35, p. 8-17.
  14. Sastre J., Mullol J., Valero A. et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr. Med. Res. Opin. 2012, v. 28, p. 121-130.
  15. Zuberbier T., Oanta A., Bogacka E. et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010, v. 65, p. 516-528.
  16. Church M.K. Comparative inhibition by bilastine and ce-tirizine of histamine-induced wheal and flare responses in humans. Inflamm. Res. 2011, v. 60, p. 1107-1112.
  17. Tyl B., Kabbaj M., Azzam S. et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J. Clin. Pharmacol. 2012, v. 52, p. 893-903.
  18. Garcia-Gea C., Martinez J., Ballester M.R. et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum. Psychopharmacol. 2014, v. 29, p. 120-132.
  19. Farre M., Pérez-Manà C., Papaseit E. et al. Bilastine vs hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br. J. Clin. Pharmacol. 2014, v. 78, p. 970-980.
  20. Alvarez-Mon M., San Antonio E., Lucero M. et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy. 2009, v. 64, p. 551-598.
  21. Bachert C., Kuna P., San-quer F. et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Bilastine International Working Group. Allergy. 2009, v. 64, p. 158-165
  22. Kuna P, Bachert C., Nowacki Z. et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy. 2009, v. 39, p. 338-347.15



Abstract: 138

PDF (Russian): 1

Article Metrics

Metrics Loading ...



Copyright © Pharmarus Print Media, 2017

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies